Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
Authors
Keywords
Aldosterone, Mineralocorticoid receptor antagonist, Nonsteroidal, Cardiorenal, Finerenone
Journal
PHARMACOLOGICAL RESEARCH
Volume 172, Issue -, Pages 105859
Publisher
Elsevier BV
Online
2021-08-29
DOI
10.1016/j.phrs.2021.105859
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF
- (2021) João Pedro Ferreira et al. JACC-Heart Failure
- Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study
- (2021) George Bakris et al. HYPERTENSION
- Finerenone Reduces Onset of Atrial Fibrillation in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2021) Gerasimos Filippatos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Characterization of Direct Perturbations on Voltage-Gated Sodium Current by Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker
- (2021) Wei-Ting Chang et al. Biomedicines
- Cardiorenal Protection in Diabetic Kidney Disease
- (2021) Jason F. Lee et al. Endocrinology and Metabolism
- Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
- (2021) Peter Kolkhof et al. AMERICAN JOURNAL OF NEPHROLOGY
- Activation of Rac1-Mineralocorticoid Receptor Pathway Contributes to Renal Injury in Salt-Loaded db/db Mice
- (2021) Daigoro Hirohama et al. HYPERTENSION
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
- (2021) Frédéric Jaisser et al. Frontiers in Pharmacology
- Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets
- (2020) Jonatan Barrera‐Chimal et al. DIABETES OBESITY & METABOLISM
- Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease
- (2020) George Bakris et al. HYPERTENSION
- Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease
- (2020) Ningning Wan et al. JOURNAL OF HUMAN HYPERTENSION
- Identifying new cellular mechanisms of mineralocorticoid receptor activation in the heart
- (2020) Morag J. Young et al. JOURNAL OF HUMAN HYPERTENSION
- Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors
- (2020) Yongfu Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
- (2020) Takashi Wada et al. Clinical and Experimental Nephrology
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers
- (2020) Tadakatsu Nakamura et al. Clinical Pharmacology in Drug Development
- The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
- (2020) Marco Vicenzi et al. Journal of Clinical Medicine
- Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
- (2020) Volker Vallon et al. Annual Review of Physiology
- Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2020) Gerasimos Filippatos et al. CIRCULATION
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Is spironolactone the preferred renin-angiotensin-aldosterone inhibitor for protection against COVID-19?
- (2020) Christopher S. Wilcox et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
- (2020) Rajiv Agarwal et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data
- (2020) Livia Lenzini et al. PHARMACOLOGICAL RESEARCH
- Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection
- (2019) Kenneth Granberg et al. JOURNAL OF MEDICINAL CHEMISTRY
- Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
- (2019) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone
- (2019) Krister Bamberg et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: Rationale and design of the ALDOCURE trial
- (2019) Joachim Alexandre et al. AMERICAN HEART JOURNAL
- Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial
- (2019) Heerajnarain Bulluck et al. AMERICAN HEART JOURNAL
- The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward
- (2019) Patrick Rossignol et al. KIDNEY INTERNATIONAL
- A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients
- (2019) Fabian Hammer et al. KIDNEY INTERNATIONAL
- Rapid Aldosterone-Mediated Signaling in the DCT Increases Activity of the Thiazide-Sensitive NaCl Cotransporter
- (2019) Lei Cheng et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
- (2019) Rajiv Agarwal et al. LANCET
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Mitigating risk of aldosterone in diabetic kidney disease
- (2019) Marie Frimodt-Møller et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
- (2019) Sadayoshi Ito et al. HYPERTENSION
- Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects
- (2018) Manabu Kato et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
- (2018) Christoph Wanner et al. DIABETOLOGIA
- Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance
- (2018) Jana Grune et al. HYPERTENSION
- The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling
- (2018) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion
- (2018) Krister Bamberg et al. PLoS One
- Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro
- (2018) Michael Gerisch et al. DRUG METABOLISM AND DISPOSITION
- Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans
- (2018) Makiko Yamada et al. DRUG METABOLISM AND DISPOSITION
- Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease
- (2018) Akira Nishiyama HYPERTENSION RESEARCH
- Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial
- (2018) David M. Charytan et al. KIDNEY INTERNATIONAL
- Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
- (2018) Raquel González-Blázquez et al. Frontiers in Pharmacology
- Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney DiseaseNovelty and Significance
- (2017) Lionel Lattenist et al. HYPERTENSION
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor null mice: informing cell-type-specific roles
- (2017) Timothy J Cole et al. JOURNAL OF ENDOCRINOLOGY
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Coregulators as mediators of mineralocorticoid receptor signalling diversity
- (2017) Peter J Fuller et al. JOURNAL OF ENDOCRINOLOGY
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Nongenomic effects via the mineralocorticoid receptor
- (2017) Stefanie Ruhs et al. JOURNAL OF ENDOCRINOLOGY
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
- (2017) Peter Kolkhof et al. JOURNAL OF ENDOCRINOLOGY
- The role of macrophages in hypertension and its complications
- (2017) A. Justin Rucker et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury
- (2017) Jochen Dutzmann et al. PLoS One
- Mineralocorticoid receptor antagonists—pharmacodynamics and pharmacokinetic differences
- (2016) Jun Yang et al. CURRENT OPINION IN PHARMACOLOGY
- Discontinued drug therapies to treat diabetes in 2015
- (2016) Maka S. Hedrington et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies
- (2016) Silvia Lentini et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Early Aldosterone Blockade in Acute Myocardial Infarction
- (2016) Farzin Beygui et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Mineralocorticoids in the Heart and Vasculature: New Insights for Old Hormones
- (2015) Achim Lother et al. Annual Review of Pharmacology and Toxicology
- Nonsteroidal antagonists of the mineralocorticoid receptor
- (2015) Peter Kolkhof et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
- (2015) Larbi Amazit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study
- (2014) G. Montalescot et al. EUROPEAN HEART JOURNAL
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Myeloid Mineralocorticoid Receptor Activation Contributes to Progressive Kidney Disease
- (2014) L. L. Huang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Spironolactone for Heart Failure with Preserved Ejection Fraction
- (2014) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Developing Therapies for Heart Failure With Preserved Ejection Fraction
- (2014) Javed Butler et al. JACC-Heart Failure
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Aldosterone-Specific Activation of Cardiomyocyte Mineralocorticoid Receptor In Vivo
- (2013) Smail Messaoudi et al. HYPERTENSION
- Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy
- (2013) Christoph D. Schumacher et al. JOURNAL OF HYPERTENSION
- Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
- (2013) Linda F. Fried et al. NEW ENGLAND JOURNAL OF MEDICINE
- PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
- (2013) Stephen Orena et al. Frontiers in Pharmacology
- Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
- (2012) Lars Bärfacker et al. ChemMedChem
- Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease
- (2012) Bertram Pitt et al. EUROPEAN JOURNAL OF HEART FAILURE
- Neutrophil Gelatinase-Associated Lipocalin Is a Novel Mineralocorticoid Target in the Cardiovascular System
- (2012) Celine Latouche et al. HYPERTENSION
- Oxidative Stress Causes Mineralocorticoid Receptor Activation in Rat Cardiomyocytes
- (2012) Miki Nagase et al. HYPERTENSION
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction
- (2011) Robin A.P. Weir et al. EUROPEAN JOURNAL OF HEART FAILURE
- Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
- (2011) Peter Kolkhof et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment
- (2010) B. A. Borlaug et al. EUROPEAN HEART JOURNAL
- Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice
- (2010) Michael G. Usher et al. JOURNAL OF CLINICAL INVESTIGATION
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone
- (2008) P. Mulder et al. EUROPEAN HEART JOURNAL
- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More